Capricor Therapeutics Stock (NASDAQ: CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Stock

CAPRICOR THERAPEUTICS INC

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

B. Riley Securities analyst Madison El-Saadi initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy rating and announces Price Target of $21.

News

Price Target

Initiation

Analyst Ratings

CAPR

B. Riley Securities Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $21

WIIM

Capricor Therapeutics shares are trading higher. Jones Trading maintained a Buy rating on the stock.

Jones Trading analyst Catherine Novack maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and lowers the price target from $40 to $29.

Jones Trading Maintains Buy on Capricor Therapeutics, Lowers Price Target to $29

Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company&#8217;s lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD)—<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46073043/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-dystrophy" rel="noreferrer noopener">associated cardiomyopathy</a>.
DMD is an X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">respiratory, and cardiac muscles</a>.
It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45254051/vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-regulation" rel="noreferrer noopener">Vinay Prasad&#8217;s Appointment To FDA&#8217;s CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation</a>
As part of the FDA&#8217;s ongoing review, the company has been informed that an Advisory Committee meeting is not indicated at this time.
The BLA remains under Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 31, 2025.
As per some media reports, Vinay Prasad, director of the FDA&#8217;s Center for Biologics Evaluation and Research (CBER), canceled the advisory committee meeting for the company&#8217;s cell therapy for <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46057620/why-is-capricor-therapeutics-stock-trading-lower-on-monday" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, 2025, although that date is pending confirmation by the FDA. At the time of the mid-cycle review, no significant issues or major <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45882991/capricor-therapeutics-announces-key-regulatory-updates-for-its-duchenne-muscular-dystrophy-program" rel="noreferrer noopener">deficiencies were noted</a>.
Linda Marbán, CEO of Capricor, says the company has hit all key regulatory milestones as planned, including a successful pre-license inspection and a smooth mid-cycle review. With the application still under Priority Review, she believes Capricor is in a strong position heading into the PDUFA date.
Capricor recently presented four-year data from its HOPE-2 Open-Label Extension (OLE) study at the 2025 Parent Project Muscular Dystrophy (PPMD) Conference, representing one of the longest-running treatment datasets in DMD, including measures of both cardiac and skeletal muscle function.
Price Action: CAPR stock is up 20% at $9.22 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46078179/pudgy-penguins-eyes-top-3-meme-spot-alongside-dogecoin-shiba-inu-after-nasdaq-spotlight-with-vaneck" target="_blank" rel="noreferrer noopener">Pudgy Penguins Eyes Top 3 Meme Spot Alongside Dogecoin, Shiba Inu After Nasdaq Spotlight With VanEck</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

Reuters Cites HHS Spokesperson Saying U.S. FDA Is Actively Reevaluating Whether To Proceed With The Advisory Committee Meeting For Capricor Therapeutics' Cell Therapy

Capricor Therapeutics Provides Update On Deramiocel BLA, Says FDA Has Indicated An Advisory Committee Meeting Is Not Required At This Time

Capricor Therapeutics shares are trading lower after Oppenheimer maintained an Outperform rating on the stock and lowered its price target from $43 to $22.

Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">data from Benzinga Pro</a>.
According to a Friday media report, Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), canceled the advisory committee meeting for the company's cell therapy for Duchenne muscular dystrophy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46036263/capricor-reports-4-year-data-for-deramiocel-shows-sustained-benefit-in-duchenne-patients" rel="noreferrer noopener">Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients</a>
Earlier in June, the FDA&#8217;s Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the company&#8217;s lead cell therapy candidate with a Biologics License Application (BLA) under FDA review for potential approval in the treatment of <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, 2025, although that date is pending confirmation by the FDA. At the time of the mid-cycle review, no significant issues or major <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45882991/capricor-therapeutics-announces-key-regulatory-updates-for-its-duchenne-muscular-dystrophy-program" rel="noreferrer noopener">deficiencies were noted</a>.
The BLA for Deramiocel remains under priority review with a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025.
STAT News <a href="https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/">reported </a>that the FDA removed its top official overseeing cell and gene therapies shortly after a dispute with her superior over a treatment for Duchenne muscular dystrophy.
The official, Nicole Verdun, had planned to convene an advisory committee meeting to evaluate a therapy developed by Capricor Therapeutics. However, to STAT, Prasad — her superior — doubted the treatment's effectiveness and canceled the meeting, citing sources familiar with the matter.
The report also noted that some sources described ongoing tensions surrounding Verdun's management style, adding uncertainty about the reasons she was placed on leave.
Since the report on Friday, Capricor stock has plunged almost 30%.
Alliance for Regenerative Medicine (ARM), an advocacy organization, <a target="_blank" href="https://alliancerm.org/press-release/statement-on-the-departure-of-otp-director/" rel="noreferrer noopener">said</a> with five regulatory decisions pending on cell and gene therapy (CGT) products in 2025 and a burgeoning pipeline of nearly 2,000 CGT clinical trials ongoing globally, CBER and OTP must operate at the highest level of productivity, efficiency, and scientific rigor.
Price Action: CAPR stock is down 11.6% at $7.30 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and lowers the price target from $43 to $22.

Oppenheimer Maintains Outperform on Capricor Therapeutics, Lowers Price Target to $22

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) on Friday <a href="https://dmdwarrior.com/capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy/?_gl=1&#x2A;9g80lr&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA0NDUyNDkkbzQ1MiRnMSR0MTc1MDQ0NjQxOSRqMTUkbDAkaDExNjcwNDQzNDI.">released</a> four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company&#8217;s lead cell therapy candidate for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline.
Further, a subgroup analysis of patients with baseline Left Ventricular Ejection Fraction (LVEF) &gt;45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44115317/capricor-therapeutics-cell-therapy-goes-under-priority-fda-review-for-duchenne-associated-heart-condition" rel="noreferrer noopener">Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition</a>
Additionally, treatment continued to slow skeletal muscle disease progression, as measured by performance of the upper limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the <a href="https://www.benzinga.com/pressreleases/25/06/g46025161/capricor-therapeutics-announces-positive-4-year-data-from-hope-2-open-label-extension-study-of-der" target="_blank" rel="noreferrer noopener">first year (1.8 points)</a>.
Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study.
&#8220;These four-year data reinforce the strength and durability of Deramiocel&#8217;s clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,&#8221; said Linda Marbán, CEO of Capricor Therapeutics. &#8220;With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval.
CAPR Price Action: CAPR stock is down 31.75% at $8.16&nbsp;at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a></li>
</ul>
Photo: Shutterstock

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Capricor Therapeutics shares are trading lower following a report suggesting the FDA's Center for Biiologics Evaluation and Research canceled an advisory committee meeting due to skepticism about the company's therapy.

<a href="https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/">https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/</a>

'Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official'- STAT News

Capricor Therapeutics Shares Resume Trade

Capricor Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 36.5%

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock rose 84.4% to $4.21 during Friday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 43.27% to $6.99. The market value of their outstanding shares is at $944.7 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares rose 41.89% to $16.4. The market value of their outstanding shares is at $507.3 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares increased by 32.68% to $0.32. The company's market cap stands at $2.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 29.67% to $2.01. The market value of their outstanding shares is at $110.9 million. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares increased by 23.92% to $37.4. The market value of their outstanding shares is at $87.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares fell 66.7% to $0.32 during Friday's regular session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares declined by 48.89% to $0.3. The company's market cap stands at $8.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 43.12% to $36.03. The company's market cap stands at $824.3 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 22.74% to $9.22. The company's market cap stands at $545.7 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 21.64% to $4.02. The company's market cap stands at $3.4 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares fell 21.59% to $2.58. The market value of their outstanding shares is at $208.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

CTOR

GALT

LUCY

MBRX

NNNN

PCSA

QNTM

SSII

12 Health Care Stocks Moving In Friday's Intraday Session

Capricor Therapeutics Announces 4-Year Data From HOPE-2 Open-Label Extension Study Of Deramiocel In Duchenne Muscular Dystrophy; After Four Years Of Continuous Treatment, Deramiocel-Treated Patients Showed A Median Change Of -0.5 Points Compared To Baseline

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
Shares of Smith &amp; Wesson Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) fell sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46007280/smith-wesson-q4-earnings-revenue-eps-fall-short-of-estimates-as-demand-slips-headwinds-will-likely-persist">worse-than-expected fourth-quarter EPS and sales.</a>
Smith &amp; Wesson Brands reported fourth-quarter revenue of $140.8 million, missing analyst estimates of $152.41 million, according to Benzinga Pro. The company reported adjusted earnings of 20 cents per share in the fourth quarter, missing estimates of 23 cents per share.
Smith &amp; Wesson Brands shares dipped 12.6% to $9.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li>Aptevo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li>Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) dropped 6.5% to $43.51 in pre-market trading.</li>
<li>Himalaya Shipping Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NASDAQ">HSHP</a>) declined 6.3% to $6.22 in pre-market trading.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) fell 5.3% to $24.88 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

AIRO

DGNX

HSHP

MESO

SWBI

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of Cheetah Mobile Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) rose sharply in pre-market trading following <a href="https://www.benzinga.com/quote/cmcm/earnings">first-quarter results</a>.
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's quarterly sales rose to $35.69 million from $26.35 million in the year-ago period.
Cheetah Mobile shares surged 11.2% to $4.57 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) surged 129.6% to $7.85 in pre-market trading. On May 21, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split.</li>
<li>Dragonfly Energy Holdings Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares jumped 108% to $0.4534 in pre-market trading after gaining 6% on Wednesday.</li>
<li>Baiya International Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) gained 36.2% to $1.13 in pre-market trading.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) jumped 32.2% to $0.32 in pre-market trading. On Tuesday, Processa Pharmaceuticals announced the pricing of $7 million public offering.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) rose 21.2% to $98.22 in pre-market trading. GMS confirmed the receipt of $95.20 per share unsolicited buyout proposal from QXO.</li>
<li>Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) rose 19.5% to $5.57 in pre-market trading after gaining 5% on Wednesday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 15.2% to $43.74 in pre-market trading after surging over 22% on Wednesday.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) fell 13.3% to $21.31 in pre-market trading after gaining more than 16% on Wednesday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) climbed 10.4% to $1.02 in pre-market trading. GeoVax Labs recently in a filing disclosed it will sell 6.15 million common units.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares tumbled 52.8% to $2.66 in pre-market trading after surging over 142% on Wednesday.</li>
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li>PTL Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) dipped 16.2% to $0.30 in pre-market trading after surging 84% on Wednesday.</li>
<li>Cambium Networks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) declined 12.9% to $0.36 in pre-market trading after gaining over 16% on Wednesday. Cambium Networks, last month, announced it received a Nasdaq noncompliance notice.</li>
<li>Smith &amp; Wesson Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) declined 12.6% to $9.51 in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.</li>
<li>Cellectar Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 12.4% to $0.32 in pre-market trading. Cellectar Biosciences announced a 1-for-30 reverse stock split, effective June 24.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li>Aptevo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li>Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

ARQQ

BBGI

BIYA

CLRB

CMBM

CMCM

DFLI

GOVX

NWGL

OSCR

PTLE

WHLR

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $31 price target.

Roth Capital Reiterates Buy on Capricor Therapeutics, Maintains $31 Price Target

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Comments

Capricor Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL